Hookipa Pharma rises as partner Gilead begins hep B vaccine trial

Hookipa Pharma

09/05/2023 17:06

** Shares of HOOKIPA Pharma Inc  HOOK.O  up 4.5% at $1.62
    ** Biopharma co reports dosing of first patient in Gilead
Sciences Inc-led early stage trial for testing HB-400, an
experimental vaccine for chronic hepatitis B
    ** The trial aims to evaluate the safety and tolerability of
repeated doses of HB-400 
    ** HOOK in January achieved a set milestone making it
eligible for a $5 mln payment from GILD, under pact terms
    ** In 2018, Gilead licensed exclusive rights to HOOK's
arenaviral platform to develop immunotherapies for HIV and
hepatitis B virus
    ** Including session moves, HOOK stock nearly doubled in
value, so far in the year 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))